Skip to content
OpenCapital
Get started

Icahn Enterprises IEP Pharma — Goodwill

Other financials

Income statement

See full
Revenue$2.2B+18.2%
Net income-$459.0M-8.8%
EPS (diluted)-$0.71+10.1%

Balance sheet

See full
Cash & equivalents$1.3B-40.5%
Total debt$6.9B-5.9%
Total assets$12.9B-16.5%

Cash flow

See full
Operating cash flow$397.0M+318%
CapEx$114.0M+29.5%
Free cash flow$283.0M+205%

Valuation

See full
Market cap$4.9B+1.6%

Profitability

See full
Gross margin-56.5%—
Net margin-3.4%-1.3pp
FCF margin20%—

Returns & leverage

See full
Return on equity-0.1%—
Debt / equity0.7×—

Where this comes from

Reported directly by Icahn Enterprises in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Icahn Enterprises's pharma — goodwill?
Icahn Enterprises (IEP) reported pharma — goodwill of $13M in Q1 2026.
How has Icahn Enterprises's pharma — goodwill changed year-over-year?
Icahn Enterprises's pharma — goodwill decreased by 0.0% year-over-year, from $13M to $13M.
What is the long-term trend for Icahn Enterprises's pharma — goodwill?
Over 4 years (2021 to 2025), Icahn Enterprises's pharma — goodwill has grown at a 0.0% compound annual growth rate (CAGR), from $52M to $52M.
What does pharma — goodwill mean?
The carrying value of goodwill associated with the pharmaceutical segment after accounting for any impairment charges. This reflects the current valuation of intangible synergies and market advantages acquired through past business combinations.